Home › Funds › Remedium Capital Partners, LLC › CBIO
Remedium Capital Partners, LLC position in CBIO
CRESCENT BIOPHARMA INC. · Health Care
Remedium Capital Partners, LLC reported holding 361,250 shares of CBIO (CRESCENT BIOPHARMA INC.) in its Q3 2026 13F filing — a position valued at US$5.3M, representing 1.93% of its reported portfolio and ranking #6 among its reported holdings. Remedium Capital Partners, LLC has disclosed CBIO holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Remedium Capital Partners, LLC's CBIO position evolved
Remedium Capital Partners, LLC first disclosed a stake in CBIO in Q4 2025 at 361,250 shares (US$4.3M). The position peaked in Q1 2026 at 361,250 shares, worth US$6.6M. Across 4 filings, Remedium Capital Partners, LLC held the position steady without any share-count change. The most recent filing (Q3 2026) shows 361,250 shares valued at US$5.3M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 361.25K | $4.28M | New |
| Q1 2026 | 361.25K | $6.64M | Hold |
| Q2 2026 | 361.25K | $6.50M | Hold |
| Q3 2026 | 361.25K | $5.27M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CBIO and 13F data
CBIO (CRESCENT BIOPHARMA INC.) is a Health Care company. 69 other funds we track also report a position in CBIO — the largest reported positions include BVF INC/IL (US$49.5M), Fairmount Funds Management LLC (US$49.5M), Venrock Adviser, LLC (US$38.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CBIO
- BVF INC/IL 2.75M sh · $49.48M · Q2 2026
- Fairmount Funds Management LLC 2.75M sh · $49.46M · Q2 2026
- Venrock Adviser, LLC 2.13M sh · $38.40M · Q2 2026
- Logos Global Management LP 1.90M sh · $34.20M · Q2 2026
- FCPM III SERVICES B.V. 1.68M sh · $30.20M · Q2 2026
- Vestal Point Capital, LP 1.63M sh · $29.34M · Q2 2026
- Opaleye Management Inc. 1.32M sh · $23.75M · Q2 2026
- TANG CAPITAL MANAGEMENT LLC 1.16M sh · $20.88M · Q2 2026
- Boxer Capital Management, LLC 453.69K sh · $8.17M · Q2 2026
- NEXTBio Capital Management LP 372.86K sh · $5.44M · Q3 2026
- STEMPOINT CAPITAL LP 182.38K sh · $3.28M · Q2 2026
- SECTORAL ASSET MANAGEMENT INC 167.60K sh · $2.45M · Q3 2026
More on Remedium Capital Partners, LLC
FAQ
How long has Remedium Capital Partners, LLC held CBIO?
Remedium Capital Partners, LLC has disclosed CBIO holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Remedium Capital Partners, LLC's current position in CBIO?
As of Q3 2026, Remedium Capital Partners, LLC holds 361.25K shares of CBIO (CRESCENT BIOPHARMA INC.), valued at $5.27M, representing 1.93% of its reported portfolio and ranking #6.
Has Remedium Capital Partners, LLC been buying or selling CBIO?
In the latest 13F filing (Q3 2026), Remedium Capital Partners, LLC held unchanged its position in CBIO. The position peaked in Q1 2026 at 361.25K shares.
Which other funds hold CBIO?
Other major institutional holders of CBIO include BVF INC/IL, Fairmount Funds Management LLC, Venrock Adviser, LLC, among 69 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.